Article Information
PubMed
Print ISSN
Online ISSN
History
- Received January 5, 2010
- Accepted April 22, 2010
- Published online July 15, 2010.
Article Versions
- Earlier version (April 22, 2010 - 11:45).
- You are viewing the most recent version of this article.
Copyright & Usage
Copyright © 2010 by The American Society for Pharmacology and Experimental Therapeutics
Author Information
- M. J. Gnoth,
- S. Sandmann,
- K. Engel and
- M. Radtke
- Address correspondence to:
Dr. Mark Gnoth, Bayer Schering Pharma AG, Global Drug Discovery, Drug Metabolism and Pharmacokinetics, Building 468, Aprather Weg 18a, D-42096 Wuppertal, Germany. E-mail: markjean.gnoth{at}bayerhealthcare.com
Parts of this work were previously presented at the following conference: Gnoth MJ, Sandmann S, Hucke F, and Radtke M 2006 Sorafenib (NexavarTM) is a weak P-gp substrate in vitro and in vivo and exhibits high permeability. EUFEPS Conference on Membrane Drug Transporters: Impact on Drug Discovery, Development, Regulation and Usage; 2006 Sept 25–27; Copenhagen, Denmark. European Federation for Pharmaceutical Sciences, Stockholm, Sweden.